Khalid Bhatti, MD
Nephrology · Elizabethtown, KYNPI 1497824114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 370 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations.
Across 370 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$897
- Vifor Pharma, Inc.$808
- Fresenius USA Marketing, Inc.$543
- Otsuka America Pharmaceutical, Inc.$519
- Bayer$502
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,65499%
- Education$701%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 57 | $1,015 |
| Amgen(2 entities) | 47 | $897 |
| Vifor Pharma, Inc. | 54 | $808 |
| Fresenius USA Marketing, Inc. | 32 | $543 |
| Otsuka America Pharmaceutical, Inc. | 25 | $519 |
| Bayer | 29 | $502 |
| Akebia Therapeutics Inc | 19 | $325 |
| Calliditas Therapeutics US Inc. | 16 | $313 |
| Ardelyx, Inc. | 14 | $310 |
| Travere Therapeutics, Inc. | 9 | $197 |
| GSK | 10 | $161 |
| Aurinia Pharma U.S., Inc. | 7 | $146 |
| Mallinckrodt Hospital Products Inc. | 7 | $145 |
| Novo Nordisk | 7 | $129 |
| Rhythm Pharmaceuticals, Inc. | 2 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Lundbeck LLC | 4 | $70 |
| OPKO Pharmaceuticals, LLC | 4 | $61 |
| Ultragenyx Pharmaceutical Inc. | 3 | $56 |
| Novartis | 3 | $51 |
| Lilly USA, LLC | 2 | $42 |
| Nxstage Medical, Inc. | 2 | $36 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Pharmacosmos Therapeutics Inc. | 2 | $25 |
| Cormedix Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
How this compares
$6,724 in reported general payments places this provider in the 85th percentile of 165 nephrology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 34 | $116,088 |
| FarxigaDapagliflozin Propanediol | 107 | $84,536 |
| EliquisApixaban | 40 | $30,978 |
| JardianceEmpagliflozin | 49 | $30,477 |
| LokelmaSodium Zirconium Cyclosilicate | 33 | $27,202 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 96 | $25,659 |
| Lanthanum Carbonate | 16 | $22,659 |
| ProsolParenteral Amino Acid 20% No.1 | 113 | $20,538 |
| JanuviaSitagliptin Phosphate | 15 | $16,995 |
| KerendiaFinerenone | 17 | $15,795 |
| Sevelamer Carbonate | 87 | $13,116 |
| OzempicSemaglutide | 12 | $11,378 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $10,781 |
| EntrestoSacubitril/Valsartan | 11 | $7,117 |
| Calcium Acetate | 120 | $5,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,015 | $111,738140 claims |
| BayerKerendia | $502 | $15,79517 claims |
| Novo NordiskOzempic | $129 | $11,37812 claims |
| NovartisEntresto | $51 | $7,11711 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $14 | $1,11436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 nephrology providers in Kentucky.
Other nephrology in Elizabethtown
- Mustafa MuhammadElizabethtown$4K
- Danny WooLouisville$427K
- Dawn CasterLouisville$193K
- Javier Neyra LozanoLexington$181K
- Kurt SowersHazard$119K
- Nizar AttallahLouisville$113K
- Ravinder BhagrathPikeville$84K
- Shafic Abdul Wahab El HindiLouisville$45K
- George AronoffLouisville$26K
- Sadiq AhmedLexington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.